Febit is setting up the Biomarker Discovery Center Heidelberg, a project with funding from the Excellence Cluster Initiative of the German Federal Ministry of Education and Research (BMBF).
The projects of the companies involved in the Biotech Excellence Cluster Rhine-Neckar were granted a total of EUR40m for the development of drugs, diagnostics and technologies in cellular and molecular biology.
In mid-February, Febit will start combining microarray technology and high-throughput sequencing (next generation sequencing) to create powerful procedures for the development and validation of novel biomarkers.
Febit's second project aims at the determination of tumour markers.
Collaborating with the German Cancer Research Center (DKFZ), Febit will conduct studies directed at the identification of markers for various cancer types and develop these into standardised diagnostic assays.
